{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:42:24Z","timestamp":1790336544093,"version":"4.1.0"},"reference-count":36,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T00:00:00Z","timestamp":1600732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201700040I\/HHSN2720008"],"award-info":[{"award-number":["HHSN272201700040I\/HHSN2720008"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>The use of antibiotics is a vital means of treating infections caused by the bacteria Bacillus (B.) anthracis. Importantly, with the potential future use of multidrug-resistant strains of B. anthracis as bioweapons, new antibiotics are needed as alternative therapeutics. In this blinded study, we assessed the protective efficacy of teixobactin, a recently discovered antibiotic, against inhalation anthrax infection in the adult rabbit model. New Zealand White rabbits were infected with a lethal dose of B. anthracis Ames spores via the inhalation route, and blood samples were collected at various times to assess antigenemia, bacteremia, tissue bacterial load, and antibody production. Treatments were administered upon detection of B. anthracis protective antigen in the animals\u2019 sera. For comparison, a fully protective dose of levofloxacin was used as a positive control. Rabbits treated with teixobactin showed 100% survival following infection, and the bacteremia was completely resolved by 24\u201348 h post-treatment. In addition, the bacterial\/spore loads in tissues of the animals treated with teixobactin were either zero or dramatically less relative to that of the negative control animals. Moreover, microscopic evaluation of the tissues revealed decreased pathology following treatment with teixobactin. Overall, these results show that teixobactin was protective against inhalation anthrax infection in the rabbit model, and they indicate the potential of teixobactin as a therapeutic for the disease.<\/jats:p>","DOI":"10.3390\/pathogens9090773","type":"journal-article","created":{"date-parts":[[2020,9,22]],"date-time":"2020-09-22T09:40:56Z","timestamp":1600767656000},"page":"773","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Teixobactin Provides Protection against Inhalation Anthrax in the Rabbit Model"],"prefix":"10.3390","volume":"9","author":[{"given":"William S.","family":"Lawrence","sequence":"first","affiliation":[{"name":"Department of Microbiology &amp; Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"},{"name":"Institute for Human Infections &amp; Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1955-9376","authenticated-orcid":false,"given":"Jennifer E.","family":"Peel","sequence":"additional","affiliation":[{"name":"Department of Microbiology &amp; Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satheesh K.","family":"Sivasubramani","sequence":"additional","affiliation":[{"name":"Directorate of Environmental Health Effects Laboratory, Naval Medical Research Unit, Dayton, OH 45433, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace B.","family":"Baze","sequence":"additional","affiliation":[{"name":"Department of Comparative Medicine, University of Texas MD Anderson Cancer Center, Bastrop, TX 78602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elbert B.","family":"Whorton","sequence":"additional","affiliation":[{"name":"Institute for Human Infections &amp; Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W. C.","family":"Beasley","sequence":"additional","affiliation":[{"name":"Department of Microbiology &amp; Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"},{"name":"Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason E.","family":"Comer","sequence":"additional","affiliation":[{"name":"Department of Microbiology &amp; Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"},{"name":"Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dallas E.","family":"Hughes","sequence":"additional","affiliation":[{"name":"NovoBiotic Pharmaceuticals, LLC, Cambridge, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Losee L.","family":"Ling","sequence":"additional","affiliation":[{"name":"NovoBiotic Pharmaceuticals, LLC, Cambridge, MA 02138, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny W.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Microbiology &amp; Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"},{"name":"Institute for Human Infections &amp; Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1001\/jama.286.20.2554","article-title":"Death due to bioterrorism-related inhalational anthrax: Report of 2 patients","volume":"286","author":"Borio","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Bioterrorism-related inhalational anthrax: The first 10 cases reported in the United States","volume":"7","author":"Jernigan","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Savransky, V., Ionin, B., and Reece, J. (2020). Current status and trends in prophylaxis and management of anthrax disease. Pathogens, 9.","DOI":"10.3390\/pathogens9050370"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0041-0101(01)00161-1","article-title":"Toxins of Bacillus anthracis","volume":"39","author":"Brossier","year":"2001","journal-title":"Toxicon"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s000180050399","article-title":"Anthrax toxins","volume":"55","author":"Duesbery","year":"1999","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1146\/annurev.micro.55.1.647","article-title":"Anthrax","volume":"55","author":"Mock","year":"2001","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s00018-004-4251-4","article-title":"Anthrax lethal toxin: A weapon of multisystem destruction","volume":"61","author":"Agrawal","year":"2004","journal-title":"Cell. Mol. Life. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mam.2009.06.002","article-title":"Anthrax toxins: A weapon to systematically dismantle the host immune defenses","volume":"30","author":"Tournier","year":"2009","journal-title":"Mol. Aspects Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1359-6446(03)02847-2","article-title":"Prevention and treatment of bacterial diseases caused by bacterial bioterrorism threat agents","volume":"8","author":"Greenfield","year":"2003","journal-title":"Drug Discov. Today"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.2174\/092986711797636036","article-title":"New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis","volume":"18","author":"Beierlein","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1592\/phco.2006.26.1.3","article-title":"Antibiotic selection and resistance issues with fluoroquinolones and doxycycline against bioterrorism agents","volume":"26","author":"Brouillard","year":"2006","journal-title":"Pharmacother. J. Hum. Phapyrmacol. Drug Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature14098","article-title":"A new antibiotic kills pathogens without detectable resistance","volume":"517","author":"Ling","year":"2015","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14787210.2019.1550357","article-title":"Teixobactin: A novel anti-infective agent","volume":"17","author":"McCarthy","year":"2019","journal-title":"Expert Rev. Anti. Infect. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1093\/jac\/dkv175","article-title":"Teixobactin, the first of a new class of antibiotics discovered by iChip technology?","volume":"70","author":"Piddock","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.18433\/J30894","article-title":"Application of iChip to grow \u201cuncultivable\u201d microorganisms and its impact on antibiotic discovery","volume":"18","author":"Sherpa","year":"2015","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17197","DOI":"10.1038\/s41598-017-17606-5","article-title":"Binding modes of Teixobactin to lipid II: Molecular dynamics study","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1128\/AAC.01050-16","article-title":"Dual targeting of cell wall precursors by Teixobactin leads to cell lysis","volume":"60","author":"Homma","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1002\/chem.201704167","article-title":"Chemistry and biology of Teixobactin","volume":"24","author":"Guo","year":"2018","journal-title":"Chem. Eur. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.tim.2017.01.004","article-title":"Multidrug-resistant enterococcal infections: New compounds, novel antimicrobial therapies?","volume":"25","author":"Willems","year":"2017","journal-title":". Trends Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1128\/MMBR.00016-07","article-title":"Lipid intermediates in the biosynthesis of bacterial peptidoglycan","volume":"71","year":"2007","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-micro-092412-155620","article-title":"Wall teichoic acids of gram-positive bacteria","volume":"67","author":"Brown","year":"2013","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-micro-091213-112949","article-title":"Lipoteichoic acid synthesis and function in gram-positive bacteria","volume":"68","author":"Percy","year":"2014","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/cbic.200900557","article-title":"Wall teichoic acid function, biosynthesis, and inhibition","volume":"11","author":"Swoboda","year":"2010","journal-title":"Chembiochem"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1369-5274(02)00359-4","article-title":"Therapeutic challenges posed by bacterial bioterrorism threats","volume":"5","author":"Gilligan","year":"2002","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.12998\/wjcc.v3.i1.20","article-title":"Anthrax: A disease of biowarfare and public health importance","volume":"3","author":"Goel","year":"2015","journal-title":"World, J. Clin. Cases"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e00788-17","DOI":"10.1128\/AAC.00788-17","article-title":"Evaluation of combination drug therapy for treatment of antibiotic-resistant inhalation anthrax in a murine model","volume":"61","author":"Heine","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/08998280.2005.11928074","article-title":"Anthrax: A continuing concern in the era of bioterrorism","volume":"18","author":"Riedel","year":"2005","journal-title":"Proc. Bayl. Univ. Med. Cent."},{"key":"ref_28","unstructured":"(2020, August 10). Products Approved for Anthrax, Available online: https:\/\/www.fda.gov\/drugs\/bioterrorism-and-drug-preparedness\/products-approved-anthrax."},{"key":"ref_29","unstructured":"(2020, August 10). National Preparedness: DHS and HHS Can Further Strengthen Coordination for Chemical, Biological, Radiological, and Nuclear Risk Assessments, Available online: https:\/\/www.gao.gov\/new.items\/d11606.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1128\/AAC.01050-06","article-title":"Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model","volume":"51","author":"Heine","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","first-page":"28","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monkey","volume":"54","author":"Henderson","year":"1956","journal-title":"Epidemiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1128\/IAI.01875-06","article-title":"Murine aerosol challenge model of anthrax","volume":"75","author":"Loving","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax","volume":"167","author":"Friedlander","year":"1993","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6804a1","article-title":"Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019","volume":"68","author":"Bower","year":"2019","journal-title":"MMWR Recomm. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cvex.2013.01.002","article-title":"Gastrointestinal disease in guinea pigs and rabbits","volume":"16","author":"DeCubellis","year":"2013","journal-title":"Vet. Clin. North Am. Exot. Anim. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1093\/clinids\/20.Supplement_2.S242","article-title":"Clostridial disease of the gut","volume":"20","author":"Borriello","year":"1995","journal-title":"Clin. Infect. Dis."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/9\/9\/773\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:12:16Z","timestamp":1760177536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/9\/9\/773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,22]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["pathogens9090773"],"URL":"https:\/\/doi.org\/10.3390\/pathogens9090773","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,22]]}}}